Immusoft, based in Seattle, WA, is a pioneering biotechnology company specializing in programming B cells to serve as biofactories for delivering personalized protein therapeutics to patients. Their innovative approach, known as Immune System Programming (ISP), involves collecting and programming B cells to produce therapeutic proteins, which are then infused back into the patient to provide long-lasting benefits.
Led by experienced professionals such as CEO Sean Ainsworth and Chief Medical Officer Dr. Robert Sikorski, Immusoft is at the forefront of developing groundbreaking technologies that have the potential to revolutionize the field of biomedicine. With a focus on advancing clinical development and improving patient outcomes, the company's cutting-edge research pipeline and dedicated team are driving the future of personalized medicine.
Generated from the website